EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

Jang Won Son, Soo Lim

Endocrinology and Metabolism · 2024

DOI: 10.3803/enm.2024.1940 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism, 2024. Verfasst von Jang Won Son und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea. Hauptthemen laut MEDLINE: Obesity, Glucagon-Like Peptide 1. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a significant risk factor for health issues like type 2 diabetes and cardiovascular disease. It often proves resistant to traditional lifestyle interventions, prompting a need for more precise therapeutic strategies. This has led to a focus on signaling pathways and neuroendocrine mechanisms to develop targeted obesity treatments. Recent developments in obesity management have been revolutionized by introducing novel glucagon-like peptide-1 (GLP-1) based drugs, such as semaglutide and tirzepatide. These drugs are part of an emerging class of nutrient-stimulated hormone-based therapeutics, acting as incretin mimetics to target G-protein–coupled receptors like GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon. These receptors are vital in regulating body fat and energy balance. The development of multiagonists, including GLP-1–glucagon and GIP–GLP-1–glucagon receptor agonists, especially with the potential for glucagon receptor activation, marks a significant advancement in the field. This review covers the development and clinical efficacy of various GLP-1-based therapeutics, exploring the challenges and future directions in obesity management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityGlucagon-Like Peptide 1HumansGlucagon-Like PeptidesObesity ManagementAnimalsAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Stichwörter der Autor:innen

GlucagonGlucagon-like peptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptideMultiagonistObesity

Substanzen

Glucagon-Like Peptide 1Glucagon-Like PeptidesAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Autor:innen und Institutionen

  • Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

Zitieren

APA

Son, J. W., & Lim, S. (2024). Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management. Endocrinology and Metabolism. https://doi.org/10.3803/enm.2024.1940

Vancouver

Son JW, Lim S. Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management. Endocrinology and Metabolism. 2024. doi:10.3803/enm.2024.1940

BibTeX
@article{Son2024,
  author = {Son, Jang Won and Lim, Soo},
  title = {Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management},
  journal = {Endocrinology and Metabolism},
  year = {2024},
  doi = {10.3803/enm.2024.1940}
}
Kostenlos starten →